NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-58) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 11/22/2024. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-35) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 02/03/2023. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-23) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 06/03/2022. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-9) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 04/13/2021. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-13) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 04/07/2021. Application Category: BLA, Application Number: 761115, Application Classification:

Submission status for IMMUNOMEDICS INC's drug TRODELVY (SUPPL-5) with active ingredient SACITUZUMAB GOVITECAN-HZIY has changed to 'Approval' on 04/07/2021. Application Category: BLA, Application Number: 761115, Application Classification:

NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.

SC 13G/A - IMMUNOMEDICS INC (0000722830) (Subject)